Agenus to Unveil Strategic Advancements and Key Milestones in Virtual Stakeholder Briefing on August 27, 2025

Agenus will host a virtual Stakeholder Briefing on August 27, 2025, featuring presentations from senior management and industry thought leaders on the company's immuno-oncology pipeline, including botensilimab (BOT) and balstilimab (BAL) program, and upcoming milestones in metastatic colorectal cancer treatment. The session will include a strategic and financial overview, achievements from the Zydus partnership closing, and insights into patient needs and potential breakthroughs in immuno-oncology.

Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments in cancer treatment [1].

The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A [1].

Key speakers include Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Jennifer Buell, PhD, CEO of MiNK Therapeutics and Chair of the Executive Committee of Agenus; Richard M. Goldberg, MD, Chief Development Officer of Agenus; and Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University [1].

The event is expected to provide detailed updates on the company's clinical and regulatory progress, including the recent regulatory alignment for the Phase 3 BATTMAN trial, which is anticipated to commence in Q4 2025 [2]. The session will also highlight the company's strategic partnerships, such as the collaboration with Zydus Lifesciences, which is expected to close in Q3 2025 with a $91M capital infusion [2].

Agenus's immuno-oncology pipeline includes botensilimab (BOT), a multifunctional, human Fc enhanced CTLA-4 blocking antibody, and balstilimab (BAL), a novel, fully human monoclonal IgG4 PD-1 antibody. Together, these therapies are designed to trigger robust and durable immune attacks against "cold" tumors, offering new hope where standard therapies have failed [2].

The virtual Stakeholder Briefing will be an opportunity for investors and financial professionals to gain a comprehensive understanding of Agenus's strategic advancements, clinical progress, and future outlook in the immuno-oncology space.

References:
[1] https://www.businesswire.com/news/home/20250819274234/en/Agenus-to-Unveil-BOTBAL-Strategic-Advancements-Key-Milestones-and-Future-Outlook-in-Virtual-Stakeholder-Briefing-on-August-27-2025
[2] https://www.biospace.com/agenus-announces-second-quarter-2025-financial-results-and-virtual-meeting-to-discuss-strategic-progress